Results 81 to 90 of about 32,586 (241)

The Concise Guide to PHARMACOLOGY 2025/26: Enzymes

British Journal of Pharmacology, Volume 182, Issue S1, Page S307-S403, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Doriano Fabbro, Alasdair J. Gibb, Eamonn Kelly, Alistair A. Mathie, Chloe J. Peach, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Stephanie Annett, Detlev Boison, Kathryn Elisa Burns, Carmen Dessauer, Jürg Gertsch, Nuala Ann Helsby, Angelo A. Izzo, Rennolds Ostrom, Ester Pagano, Andreas Papapetropoulos, Nigel J. Pyne, Susan Pyne, Tracy Robson, Roland Seifert, Johannes‐Peter Stasch, Csaba Szabo, Mario van der Stelt, Albert van der Vliet, Val Watts, Szu Shen Wong   +31 more
wiley   +1 more source

Fondaparinux in the management of patients with ST-elevation acute myocardial infarction

Vascular Health and Risk Management, 2006
Alexander GG TurpieHamilton Health Sciences Corporation – General Division, Hamilton, ON, CanadaAbstract: The death rate of patients with ST-segment elevation myocardial infarction (STEMI) remains substantial.
Alexander GG Turpie
doaj  

Effective use of fondaparinux in patient with unresponsiveness to nadroparin

Journal of Clinical Pharmacy and Therapeutics, 2020
Fondaparinux exhibits a similar mechanism of action as LMWH. Since both of these drugs bind to antithrombin and increase its affinity to factor Xa, fondaparinux is not expected to be an effective alternative anticoagulant to LMWH in case of LMWH ...
J. Hartinger, A. Svobodova, I. Malikova, R. Šachl, O. Slanař   +4 more
semanticscholar   +1 more source

Delphi Consensus Among French Obesity Experts on Clinical Recommendations for Drug Prescription in Patients With Severe Obesity

Obesity Reviews, Volume 26, Issue 12, December 2025.
ABSTRACT Introduction Although the physiologic alterations seen in obesity often affect the pharmacokinetics and pharmacodynamics of drugs, most clinical trials do not consider these aspects specifically for this population. To date, there is no list of potentially inappropriate medications for patients living with obesity. The aim of this study was to
Sarah Berdot, Germain Perrin, Emmanuel Disse, Armelle Arnoux, Eric Bertin, Anne‐Laure Borel, Marie‐Claude Brindisi, Arnaud De Luca, Edouard‐Jules Laforgue, Jean‐Daniel Lalau, Yann Matussiere, Emilie Montastier, Agnès Sallé, Bérénice Segrestin, Valentine Suteau, French Hospital Expert Panel, Sebastien Czernichow, Brigitte Sabatier   +17 more
wiley   +1 more source

Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis

BMC Cardiovascular Disorders, 2017
Background Enoxaparin and Fondaparinux are potential anticoagulants which are used peri-operatively in the management of patients with Acute Coronary Syndrome (ACS).
Pravesh Kumar Bundhun, Musaben Shaik, Jun Yuan   +2 more
doaj   +1 more source

The impact of socio‐economic deprivation on the long‐term survival of people with diabetes and acute myocardial infarction: A nationwide cohort study

Diabetic Medicine, Volume 42, Issue 11, November 2025.
Graphical Abstract summarising key study findings. Abstract Background People from areas of socio‐economic deprivation have poorer outcomes following acute myocardial infarction (AMI). How deprivation influences the survival of people with diabetes mellitus (DM) post‐AMI is not well described.
Nicholas Weight, Andrew Cole, Muhammad Rashid, Kamlesh Khunti, Shivani Misra, Evangelos Kontopantelis, Thomas A. Shepherd, Martin K. Rutter, Mamas A. Mamas   +8 more
wiley   +1 more source

Management of acute coronary syndromes with fondaparinux

Vascular Health and Risk Management, 2007
Harm Wienbergen, Uwe ZeymerHerzzentrum Ludwigshafen, Medizinische Klinik B, GermanyAbstract: Fondaparinux is the first selective inhibitor of the coagulation factor Xa which is commercially avaliable for clinical use.
Harm Wienbergen, Uwe Zeymer
doaj  

Glycosaminoglycans as Polyelectrolytes: Charge, Interactions, and Applications

ChemBioChem, Volume 26, Issue 20, October 31, 2025.
Glycosaminoglycans (GAGs) are linear, anionic biopolymers with their functions tightly linked to their charge. This review approaches GAGs from a polyelectrolyte perspective, shedding light on how the distribution of sulfate groups and, thus, negative charges, governs their interactions with other biomolecules.
Gergo Peter Szekeres, Eunjin Moon, Johanna K. Elter, Bryce Roper, Jayachandran Narayanan Nair Kizhakkedathu, Matthias Ballauff, Rainer Haag, Kevin Pagel   +7 more
wiley   +1 more source

IgG and IgM Anti‐Phosphatidylserine/Prothrombin Complex Antibody Detection May Improve Classification Accuracy of Systemic Lupus Erythematosus and Antiphospholipid Antibody Syndrome

ACR Open Rheumatology, Volume 7, Issue 10, October 2025.
Objective Antiphospholipid antibody (aPL) syndrome (APS) classification requires a thrombotic event and detection of lupus anticoagulant (LAC), anticardiolipin antibodies (aCL), or anti–β2‐glycoprotein I (anti‐β2GPI) antibodies on two occasions ≥12 weeks apart. Here, we investigated the utility of anti–phosphatidylserine/prothrombin complex (anti‐PS/PT)
Christina Donath, Sara Kahlown, Liye Suo, Katalin Banki, Andras Perl   +4 more
wiley   +1 more source

Investigação recente em antitrombóticos. Novidades para o tratamento dos doentes com síndromas coronárias agudas [PDF]

, 2010
A terapêutica antitrombótica ocupa um lugar central no tratamento da doença coronária aguda. A sua importância foi reforçada com a generalização dos procedimentos de intervenção percutânea, em especial quando são implantados dispositivos intra-coronários.
Morais, João
core